{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:17:28Z","timestamp":1794946648217,"version":"4.9.1"},"reference-count":41,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Seven immunocompetent patients aged &gt; 50 years old presented with herpes zoster (HZ) infection in a median of 9 days (range 7\u201320) after vaccination against SARS-CoV-2. The occurrence of HZ within the time window 1\u201321 days after vaccination defined for increased risk and the reported T cell-mediated immunity involvement suggest that COVID-19 vaccination is a probable cause of HZ. These cases support the importance of continuing assessment of vaccine safety during the ongoing massive vaccination for the COVID-19 pandemic and encourage reporting and communication of any vaccination-associated adverse event.<\/jats:p>","DOI":"10.3390\/vaccines9060572","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T23:07:03Z","timestamp":1622588823000},"page":"572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3000-8447","authenticated-orcid":false,"given":"Mina","family":"Psichogiou","sequence":"first","affiliation":[{"name":"First Department of Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-9712","authenticated-orcid":false,"given":"Michael","family":"Samarkos","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Mikos","sequence":"additional","affiliation":[{"name":"Allergology Department, Laiko General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Hatzakis","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Garcia-Montero, C., Fraile-Martinez, O., Bravo, C., Torres-Garranza, D., Sanchez-Trujillo, L., Gomez-Lahoz, A.M., Guijarro, L.G., Garcia-Honduvilla, N., Asunsolo, A., and Bujan, J. (2021). An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic times. Vaccines, 9.","DOI":"10.3390\/vaccines9050433"},{"key":"ref_3","unstructured":"WHO Coronavirus (COVID-19) Dashboard (2021, May 29). Geneva: World Health Organization. 5 April 2021. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_4","first-page":"83","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"n567","DOI":"10.1136\/bmj.n567","article-title":"Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1016\/j.vaccine.2012.09.074","article-title":"Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"30","author":"Loughlin","year":"2012","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Psichogiou, M., Karabinis, A., Pavlopoulou, I.D., Basoulis, D., Petsios, K., Roussos, S., Pratikaki, M., Jahaj, E., Protopapas, K., and Leontis, K. (2020). Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. PLoS ONE, 15.","DOI":"10.1101\/2020.06.23.20137620"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/320169","article-title":"Herpes zoster in older adults","volume":"32","author":"Schmader","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/infdis\/jiz652","article-title":"The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults \u226550 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence","volume":"222","author":"Tseng","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/ciw296","article-title":"Increasing incidence of Herpes Zoster over a 60-year period from a population-based study","volume":"63","author":"Kawai","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cid\/ciy953","article-title":"The epidemiology of Herpes Zoster in the United States during the era of Varicella and Herpes Zoster Vaccines: Changing patterns among older Adults","volume":"69","author":"Harpaz","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","first-page":"e8998","article-title":"Herpes Zoster Co-Infection in an Immunocompetent Patient With COVID-19","volume":"12","author":"Saati","year":"2020","journal-title":"Cureus"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/ene.14361","article-title":"COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy","volume":"27","author":"Ferreira","year":"2020","journal-title":"Eur. J. Neurol"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/ijd.15001","article-title":"Herpes zoster in COVID-19-positive patients","volume":"59","author":"Tartari","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_15","first-page":"318","article-title":"Herpes zoster may be a marker for COVID-19 infection during pregnancy","volume":"106","author":"Elsaie","year":"2020","journal-title":"Cutis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/eujp.2000.0186","article-title":"The development and validation of a Greek version of the short-form McGill Pain Questionnaire","volume":"4","author":"Georgoudis","year":"2000","journal-title":"Eur. J. Pain."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical Practice. Herpes Zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4065\/mcp.2010.0618","article-title":"Herpes Zoster recurrences more frequent than previously reported","volume":"86","author":"Yawn","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/00002030-199510000-00006","article-title":"Herpes Zoster, immunological deterioration and disease progression in HIV-1 infection","volume":"9","author":"Veenstra","year":"1995","journal-title":"AIDS"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., and Creech, C.B. (2020). Efficacy and Safety of the mRNA-1273, SARS-CoV-2 Vaccine. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2035389"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/000164802760370736","article-title":"Bell\u2019s palsy: The spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies","volume":"549","author":"Peitersen","year":"2002","journal-title":"Acta Otolaryngol. Suppl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/jnnp.71.2.149","article-title":"Ramsay Hunt Syndrome","volume":"71","author":"Sweeney","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1086\/515019","article-title":"High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors","volume":"27","author":"Gatell","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0140-6736(99)00623-6","article-title":"Reactivation of herpesvirus infections after vaccinations?","volume":"353","author":"Walter","year":"1999","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1708-8305.2006.00098.x","article-title":"Herpes Zoster after Yellow Fever Vaccination","volume":"14","author":"Bayas","year":"2007","journal-title":"J. Travel. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/bjo.2010.185983","article-title":"Reactivation of acute retinal necrosis after flu H1N1 vaccination","volume":"95","author":"Rothova","year":"2011","journal-title":"Br. J. Ophtalmol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bostan, E., and Yalici-Armagan, B.J. (2021). Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?. Cosmet. Dermatol.","DOI":"10.1111\/jocd.14035"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Furer, V., Zisman, D., Kibari, A., Rimar, D., Paran, Y., and Elkayam, O. (2021). Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: A case series. Rheumatology.","DOI":"10.1093\/rheumatology\/keab345"},{"key":"ref_30","unstructured":"(2021, April 04). VAERS Searches: United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC)\/Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990\u20143\/26\/2021, CDC WONDER On-line Database, Available online: http:\/\/wonder.cdc.gov\/vaers.html."},{"key":"ref_31","unstructured":"(2021, April 04). Coronavirus Vaccine\u2014Weekly Summary of Yellow Card Reporting. Updated 25 March 2021, Available online: https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting."},{"key":"ref_32","unstructured":"(2021, April 04). COVID-19 Vaccine AstraZeneca Analysis Print, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/975786\/COVID-19_AstraZeneca_Vaccine_Analysis_Print.pdf."},{"key":"ref_33","unstructured":"(2021, April 04). COVID-19 mRNA Pfizer- BioNTech Vaccine Analysis Print, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/975808\/COVID-19_mRNA_Pfizer-BioNTech_Vaccine_Analysis_Print.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun. Ageing"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L.M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., and Baum, A. (2020). BNT162b2 induces SARS-CoV-2 neutralizing antibodies and T cells in humans. medRxiv.","DOI":"10.1038\/s41586-021-03653-6"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273, Vaccine in older individuals","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1016\/j.vaccine.2012.04.005","article-title":"Algorithm to assess causality after individual adverse events following immunizations","volume":"30","author":"Halsey","year":"2012","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","article-title":"Assessment of causality of individual adverse events following immunization (AEFI): A WHO tool for global use","volume":"31","author":"Tozzi","year":"2013","journal-title":"Vaccine"},{"key":"ref_39","unstructured":"Shimabukuro, T. (2021, January 27). COVID-19 Vaccine Safety Update. Proceedings of the Advisory Committee on Immunization Practices (ACIP) Meeting, Atlanta, GA, USA."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1056\/NEJMra2035343","article-title":"Maintaining safety with SARS-CoV-2 Vaccines","volume":"384","author":"Castells","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/6\/572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:43Z","timestamp":1760162983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/6\/572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["vaccines9060572"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9060572","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}